Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients

doi:10.4251/wjgo.v13.i12.2149

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 12

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3910)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

184

WORD

118

HTML

1402

Figures (1-2)

128

Tables (1-3)

200

Sum=2032

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

323

Download

614

Sum=937

Publishing Process of This Article

Item

Count

Browse

310

Download

631

Sum=941

Dec 15, 2021 (publication date) through May 2, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Dec 15, 2021; 13(12): 2149-2160
Published online Dec 15, 2021. doi: 10.4251/wjgo.v13.i12.2149

Open in New Tab Full Size Figure Download Figure

Figure 1 Scenario calculations of percentage of time up-to-date with surveillance.

Open in New Tab Full Size Figure Download Figure

Figure 2 Distribution of participants within percentage of time up-to-date with hepatocellular carcinoma surveillance categories.

Citation: Low ES, Apostolov R, Wong D, Lin S, Kutaiba N, Grace JA, Sinclair M. Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. World J Gastrointest Oncol 2021; 13(12): 2149-2160
URL: https://www.wjgnet.com/1948-5204/full/v13/i12/2149.htm
DOI: https://dx.doi.org/10.4251/wjgo.v13.i12.2149